{
    "title": "112_hr2951",
    "content": "The \"Patients First Act of 2011\" aims to intensify research for improved understanding and treatments of diseases, promote ethical stem cell research and human clinical trials, and encourage the derivation of pluripotent stem cell lines without creating or harming human embryos. The \"Patients First Act of 2011\" promotes ethical stem cell research and human clinical trials, including the derivation of pluripotent stem cell lines without harming human embryos. SEC. 409K focuses on human stem cell research and therapy. The Secretary conducts research on stem cells for disease treatments, prioritizing those with clinical benefits, without creating or harming human embryos. The Secretary will issue guidelines within 90 days to ensure that research supported under this section is consistent with established standards and prioritized for potential clinical benefits in human patients. The section outlines criteria for evidence of improvement in human patients or FDA approval for human trials. Definitions include 'human embryo' and 'risk of injury'. The term 'risk of injury' refers to subjecting a human embryo to a greater risk of injury or death than allowed for research on fetuses in utero. The Secretary of Health shall prioritize human stem cell research in accordance with section 409K and submit annual reports to Congress on peer-reviewed research proposals. The Secretary of Health shall prioritize human stem cell research and submit reports to Congress on unfunded research proposals, explaining why they were not funded."
}